Clinical trial · Observational
Human Epididymis Protein 4 in Endometrial Carcinoma
Evaluation of Serum Human Epididymis Secretory Protein 4 (HE4) in Benign Endometrial Disease and Endometrial Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Endometrial cancer represents the most common gynecologic cancer, and it is expected to become an even greater public health concern as the prevalence of obesity, one of the most common risk factors for endometrial cancer, increases worldwide. Almost 20% of patients with endometrial cancer are in the premenopausal state and 10% are asymptomatic. In such a case, it is much harder to make an early diagnosis and usually they are probably diagnosed at advanced stages. An earlier diagnosis represents an imperative goal to improve survival and prognosis of patients of endometrial cancer. Actually, there are no certified screening tools for endometrial cancer. Pelvic ultrasound as screening for endometrial cancer-reaches 80.5% of sensitivity, when endometrial echo is \> 5 mm, but it dramatically decreases to 20% in asymptomatic women; moreover, specificity is low (61%).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Human epididymis protein 4 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- endometrial carcinoma( cases)
- description
- 42 patients with abnormal uterine bleeding and diagnosed endometrial cancer at prior endometrial biopsy, underwent staging laparotomy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
- interventionNames
- Diagnostic Test: Human epididymis protein 4
- label
- benign diseases(control)
- description
- 42 patients with abnormal uterine bleeding and diagnosed benign endometrial pathology by endometrial biopsy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
- interventionNames
- Diagnostic Test: Human epididymis protein 4
Primary outcomes (1)
- measure
- Relation between preoperative level of human epididymis protein 4 and surgicopathological staging of endometrial carcinoma
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 45 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age (45 - 70 yr old). Exclusion Criteria: 1. Age more than 70 yr and less than 40 yr. 2. Abnormal cardiac hematological renal hepatic functions. 3. Breast cancer or other malignancies. 4. Concomitant benign and for malignant adnexal pathologies. 5. Hormonal medication. 6. Patient taking or having chemo-radiotherapy. 7. Patients unfit for surgical intervention. 8. Smoker.
References
Publications (0)
Data not yet available